Covista: Stronger Results Keep Me Bullish, But Cash Flow Needs To Improve

Impact · against what's priced in

Covista's recent results provide a mixed outlook: strong growth at Walden is offset by stagnant margins at Chamberlain and deteriorating cash flow quality. While the top-line growth is positive, the accelerating credit loss provisions suggest potential earnings headwinds in the near term.

CVSA+0.10

No priced-in read yet

In context

Walden's 16.1% EBITDA growth suggests expanding margins, though this is tempered by declining operating cash flow and credit loss provisions rising faster than revenue.

Read from the article alone

• cash flow▲15%
• earnings▲6%
• revenue growth▲1%
• valuation
• CVSA
• ebitda
• profitability